Selected amino acid changes in HIV-1 subtype-C gp41 are associated with specific gp120V3 signatures in the regulation of co-receptor usage

Virus Research

Volumn 168, Issue 1-2, 2012, Pages 73-83

  Dimonte, Salvatore ^a   Babakir Mina, Muhammed ^b,c   Mercurio, Fabio ^a   Di Pinto, Domenico ^a   Ceccherini Silberstein, Francesca ^a   Svicher, Valentina ^a   Perno, Carlo Federico ^a,b,d  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c FOUNDATION OF TECHNICAL EDUCATION   (Iraq)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Cluster; Genotype; Gp120 V3 loop; Gp41; HIV 1; Mutations; Subtype C; Tropism

Indexed keywords

AMINO ACID; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; VIRUS PROTEIN;

ARTICLE; CLUSTER ANALYSIS; GENE SEQUENCE; GLYCOSYLATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHILICITY; NONHUMAN; PHYLOGENETIC TREE; PRIORITY JOURNAL; TROPISM;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PHYLOGENY; PROTEIN BINDING; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECEPTORS, HIV;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84864416743     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2012.06.019     Document Type: Article

References (127)

1. Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., Berger E.A. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272:1955-1958.
2. Anastassopoulou C.G., Ketas T.J., Depetris R.S., Thomas A.M., Klasse P.J., Moore J.P. Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41. Virology 2011, 413:47-59.
3. Anastassopoulou C.G., Ketas T.J., Klasse P.J., Moore J.P. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:5318-5323.
4. Arien K.K., Vanham G., Arts E.J. Is HIV-1 evolving to a less virulent form in humans?. Nature Reviews Microbiology 2007, 5:141-151.
5. Back N.K., Smit L., De Jong J.J., Keulen W., Schutten M., Goudsmit J., Tersmette M. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 1994, 199:431-438.
6. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a pratical and useful approach to multiple testing. Journal of Royal Statistical Society, Series B 1995, 57(1).
7. Berger E.A., Doms R.W., Fenyo E.M., Korber B.T., Littman D.R., Moore J.P., Sattentau Q.J., Schuitemaker H., Sodroski J., Weiss R.A. A new classification for HIV-1. Nature 1998, 391:240.
8. Blish C.A., Nguyen M.A., Overbaugh J. Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. PLoS Medicine 2008, 5:e9.
9. Carrillo A., Ratner L. Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells. Journal of Virology 1996, 70:1310-1316.
10. Cecilia D., Kulkarni S.S., Tripathy S.P., Gangakhedkar R.R., Paranjape R.S., Gadkari D.A. Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India. Virology 2000, 271:253-258.
11. Chan D.C., Fass D., Berger J.M., Kim P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89:263-273.
12. Cheung L., McLain L., Hollier M.J., Reading S.A., Dimmock N.J. Part of the C-terminal tail of the envelope gp41 transmembrane glycoprotein of human immunodeficiency virus type 1 is exposed on the surface of infected cells and is involved in virus-mediated cell fusion. Journal of General Virology 2005, 86:131-138.
13. Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P.D., Wu L., Mackay C.R., LaRosa G., Newman W., Gerard N., Gerard C., Sodroski J. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996, 85:1135-1148.
14. Choge I., Cilliers T., Walker P., Taylor N., Phoswa M., Meyers T., Viljoen J., Violari A., Gray G., Moore P.L., Papathanosopoulos M., Morris L. Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. AIDS Research and Human Retroviruses 2006, 22:458-465.
15. Choisy M., Woelk C.H., Guegan J.F., Robertson D.L. Comparative study of adaptive molecular evolution in different human immunodeficiency virus groups and subtypes. Journal of Virology 2004, 78:1962-1970.
16. Cilliers T., Nhlapo J., Coetzer M., Orlovic D., Ketas T., Olson W.C., Moore J.P., Trkola A., Morris L. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. Journal of Virology 2003, 77:4449-4456.
17. Cleveland S.M., McLain L., Cheung L., Jones T.D., Hollier M., Dimmock N.J. A region of the C-terminal tail of the gp41 envelope glycoprotein of human immunodeficiency virus type 1 contains a neutralizing epitope: evidence for its exposure on the surface of the virion. Journal of General Virology 2003, 84:591-602.
18. Clevestig P., Pramanik L., Leitner T., Ehrnst A. CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-linked glycosylation site. Journal of General Virology 2006, 87:607-612.
19. Coetzer M., Cilliers T., Ping L.H., Swanstrom R., Morris L. Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. Virology 2006, 356:95-105.
20. Coetzer M., Nedellec R., Cilliers T., Meyers T., Morris L., Mosier D.E. Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C. Journal of Acquired Immune Deficiency Syndromes 2011, 56:9-15.
21. Connor R.I., Sheridan K.E., Ceradini D., Choe S., Landau N.R. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. Journal of Experimental Medicine 1997, 185:621-628.
22. Cormier E.G., Dragic T. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. Journal of Virology 2002, 76:8953-8957.
23. de Jong J.J., Goudsmit J., Keulen W., Klaver B., Krone W., Tersmette M., de Ronde A. Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. Journal of Virology 1992, 66:757-765.
24. De Wolf F., Hogervorst E., Goudsmit J., Fenyo E.M., Rubsamen-Waigmann H., Holmes H., Galvao-Castro B., Karita E., Wasi C., Sempala S.D., Baan E., Zorgdrager F., Lukashov V., Osmanov S., Kuiken C., Cornelissen M., the WHO Network for HIV Isolation and Characterization Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. AIDS Research and Human Retroviruses 1994, 10:1387-1400.
25. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Sutton R.E., Hill C.M., Davis C.B., Peiper S.C., Schall T.J., Littman D.R., Landau N.R. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
26. V3 signatures in the regulation of co-receptor usage. Retrovirology 2011, 8:33.
27. Dimonte S., Svicher V., Salpini R., Ceccherini-Silberstein F., Perno C.F., Babakir-Mina M. HIV-2 A-subtype gp125(C2-V3-C3) mutations and their association with CCR5 and CXCR4 tropism. Archives of Virology 2011, 156:1943-1951.
28. Doranz B.J., Rucker J., Yi Y., Smyth R.J., Samson M., Peiper S.C., Parmentier M., Collman R.G., Doms R.W. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996, 85:1149-1158.
29. Dragic T., Litwin V., Allaway G.P., Martin S.R., Huang Y., Nagashima K.A., Cayanan C., Maddon P.J., Koup R.A., Moore J.P., Paxton W.A. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667-673.
30. Eckert D.M., Kim P.S. Mechanisms of viral membrane fusion and its inhibition. Annual Review of Biochemistry 2001, 70:777-810.
31. Fantini J., Garmy N., Mahfoud R., Yahi N. Lipid rafts: structure, function and role in HIV, Alzheimer's and prion diseases. Expert Reviews in Molecular Medicine 2002, 4:1-22.
32. Feng Y., Broder C.C., Kennedy P.E., Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:872-877.
33. Fortinbras PSSM, http://fortinbras.us/cgi-bin/fssm/fssm.pl.
34. Fouchier R.A., Groenink M., Kootstra N.A., Tersmette M., Huisman H.G., Miedema F., Schuitemaker H. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. Journal of Virology 1992, 66:3183-3187.
35. Gangupomu V.K., Abrams C.F. All-atom models of the membrane-spanning domain of HIV-1 gp41 from metadynamics. Biophysical Journal 2010, 99:3438-3444.
36. Garrido C., Roulet V., Chueca N., Poveda E., Aguilera A., Skrabal K., Zahonero N., Carlos S., Garcia F., Faudon J.L., Soriano V., de Mendoza C. Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. Journal of Clinical Microbiology 2008, 46:887-891.
37. Gavel Y., von Heijne G. Sequence differences between glycosylated and non-glycosylated Asn-X-Thr/Ser acceptor sites: implications for protein engineering. Protein Engineering 1990, 3:433-442.
38. Geno2Pheno [coreceptor], http://coreceptor.bioinf.mpi-inf.mpg.de/.
39. Hall T.A. BioEdit: a user-friendly biological sequence alignment, editor and analysis program for Windows 95/98 NT. Nucl Acids Symp Ser, vol. 41 1999, 95-98.
40. Hammache D., Yahi N., Pieroni G., Ariasi F., Tamalet C., Fantini J. Sequential interaction of CD4 and HIV-1 gp120 with a reconstituted membrane patch of ganglioside GM3: implications for the role of glycolipids as potential HIV-1 fusion cofactors. Biochemical and Biophysical Research Communications 1998, 246:117-122.
41. Hartley O., Klasse P.J., Sattentau Q.J., Moore J.P. V3: HIV's switch-hitter. AIDS Research and Human Retroviruses 2005, 21:171-189.
42. Helseth E., Olshevsky U., Furman C., Sodroski J. Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. Journal of Virology 1991, 65:2119-2123.
43. Hemelaar J., Gouws E., Ghys P.D., Osmanov S. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011, 25:679-689.
44. Hollier M.J., Dimmock N.J. The C-terminal tail of the gp41 transmembrane envelope glycoprotein of HIV-1 clades A, B, C, and D may exist in two conformations: an analysis of sequence, structure, and function. Virology 2005, 337:284-296.
45. Hrin R., Montgomery D.L., Wang F., Condra J.H., An Z., Strohl W.R., Bianchi E., Pessi A., Joyce J.G., Wang Y.J. Short communication: in vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV Type 1 gp41. AIDS Research and Human Retroviruses 2008, 24:1537-1544.
46. Hu Q., Trent J.O., Tomaras G.D., Wang Z., Murray J.L., Conolly S.M., Navenot J.M., Barry A.P., Greenberg M.L., Peiper S.C. Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization. Journal of Molecular Biology 2000, 302:359-375.
47. Huang C.C., Lam S.N., Acharya P., Tang M., Xiang S.H., Hussan S.S., Stanfield R.L., Robinson J., Sodroski J., Wilson I.A., Wyatt R., Bewley C.A., Kwong P.D. Structures of the CCR5N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 2007, 317:1930-1934.
48. Huang C.C., Tang M., Zhang M.Y., Majeed S., Montabana E., Stanfield R.L., Dimitrov D.S., Korber B., Sodroski J., Wilson I.A., Wyatt R., Kwong P.D. Structure of a V3-containing HIV-1 gp120 core. Science 2005, 310:1025-1028.
49. Huang W., Frantzell A., Toma J., Fransen S., Whitcomb J.M., Stawiski E., Petropoulos C.J. Mutational pathways and genetic barriers to CXCR4-mediated entry by human immunodeficiency virus type 1. Virology 2011, 409:308-318.
50. Huang W., Toma J., Fransen S., Stawiski E., Reeves J.D., Whitcomb J.M., Parkin N., Petropoulos C.J. Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. Journal of Virology 2008, 82:5584-5593.
51. Hug P., Lin H.M., Korte T., Xiao X., Dimitrov D.S., Wang J.M., Puri A., Blumenthal R. Glycosphingolipids promote entry of a broad range of human immunodeficiency virus type 1 isolates into cell lines expressing CD4, CXCR4, and/or CCR5. Journal of Virology 2000, 74:6377-6385.
52. Hunt J.S., Romanelli F. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1. Pharmacotherapy 2009, 29:295-304.
53. Jensen M.A., Li F.S., van't Wout A.B., Nickle D.C., Shriner D., He H.X., McLaughlin S., Shankarappa R., Margolick J.B., Mullins J.I. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. Journal of Virology 2003, 77:13376-13388.
54. Kasturi L., Chen H., Shakin-Eshleman S.H. Regulation of N-linked core glycosylation: use of a site-directed mutagenesis approach to identify Asn-Xaa-Ser/Thr sequons that are poor oligosaccharide acceptors. Biochemical Journal 1997, 323(Pt. 2):415-419.
55. Koito A., Stamatatos L., Cheng-Mayer C. Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120. Virology 1995, 206:878-884.
56. Innovagen, http://www.innovagen.se/.
57. Labrosse B., Treboute C., Brelot A., Alizon M. Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor. Journal of Virology 2001, 75:5457-5464.
58. Leal E., Janini M., Diaz R.S. Selective pressures of human immunodeficiency virus type 1 (HIV-1) during pediatric infection. Infection, Genetics and Evolution 2007, 7:694-707.
59. Leavitt M., Park E.J., Sidorov I.A., Dimitrov D.S., Quinnan G.V. Concordant modulation of neutralization resistance and high infectivity of the primary human immunodeficiency virus type 1 MN strain and definition of a potential gp41 binding site in gp120. Journal of Virology 2003, 77:560-570.
60. Lemey P., Kosakovsky Pond S.L., Drummond A.J., Pybus O.G., Shapiro B., Barroso H., Taveira N., Rambaut A. Synonymous substitution rates predict HIV disease progression as a result of underlying replication dynamics. PLoS Computational Biology 2007, 3:e29.
61. Lemey P., Rambaut A., Pybus O.G. HIV evolutionary dynamics within and among hosts. AIDS Reviews 2006, 8:125-140.
62. Li Y., Rey-Cuille M.A., Hu S.L. N-linked glycosylation in the V3 region of HIV type 1 surface antigen modulates coreceptor usage in viral infection. AIDS Research and Human Retroviruses 2001, 17:1473-1479.
63. Lin N., Sagar M., Becerril C., Giguel F., Novitsky V., Makhema J., Musonda R., Essex M., Kuritzkes D. Genetic determinants of co-receptor usage in HIV-1 subtype-C. Program and abstracts of the 18th Conference on Retroviruses and Opportunistic Infections 2011, (paper 178). http://www.retroconference.org/2011/Abstracts/40100.htm.
64. Losman B., Biller M., Olofsson S., Schonning K., Lund O.S., Svennerholm B., Hansen J.E., Bolmstedt A. The N-linked glycan of the V3 region of HIV-1 gp120 and CXCR4-dependent multiplication of a human immunodeficiency virus type 1 lymphocyte-tropic variant. FEBS Letters 1999, 454:47-52.
65. Malenbaum S.E., Yang D., Cavacini L., Posner M., Robinson J., Cheng-Mayer C. The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors. Journal of Virology 2000, 74:11008-11016.
66. Marshall R.D. Glycoproteins. Annual Review of Biochemistry 1972, 41:673-702.
67. McCaffrey R.A., Saunders C., Hensel M., Stamatatos L. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. Journal of Virology 2004, 78:3279-3295.
68. McCormack G.P., Glynn J.R., Crampin A.C., Sibande F., Mulawa D., Bliss L., Broadbent P., Abarca K., Ponnighaus J.M., Fine P.E., Clewley J.P. Early evolution of the human immunodeficiency virus type 1 subtype C epidemic in rural Malawi. Journal of Virology 2002, 76:12890-12899.
69. Mellquist J.L., Kasturi L., Spitalnik S.L., Shakin-Eshleman S.H. The amino acid following an asn-X-Ser/Thr sequon is an important determinant of N-linked core glycosylation efficiency. Biochemistry 1998, 37:6833-6837.
70. Mikhail M., Wang B., Lemey P., Beckthold B., Vandamme A.M., Gill M.J., Saksena N.K. Role of viral evolutionary rate in HIV-1 disease progression in a linked cohort. Retrovirology 2005, 2:41.
71. Montero M., van Houten N.E., Wang X., Scott J.K. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiology and Molecular Biology Reviews 2008, 72:54-84. (table).
72. Moscoso C.G., Sun Y., Poon S., Xing L., Kan E., Martin L., Green D., Lin F., Vahlne A.G., Barnett S., Srivastava I., Cheng R.H. Quaternary structures of HIV Env immunogen exhibit conformational vicissitudes and interface diminution elicited by ligand binding. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:6091-6096.
73. Nabatov A.A., Pollakis G., Linnemann T., Kliphius A., Chalaby M.I., Paxton W.A. Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies. Journal of Virology 2004, 78:524-530.
74. Ndung'u T., Sepako E., McLane M.F., Chand F., Bedi K., Gaseitsiwe S., Doualla-Bell F., Peter T., Thior I., Moyo S.M., Gilbert P.B., Novitsky V.A., Essex M. HIV-1 subtype C in vitro growth and coreceptor utilization. Virology 2006, 347:247-260.
75. Neil S.J., Aasa-Chapman M.M., Clapham P.R., Nibbs R.J., McKnight A., Weiss R.A. The promiscuous CC chemokine receptor D6 is a functional coreceptor for primary isolates of human immunodeficiency virus type 1 (HIV-1) and HIV-2 on astrocytes. Journal of Virology 2005, 79:9618-9624.
76. Park E.J., Quinnan G.V. Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains. Journal of Virology 1999, 73:5707-5713.
77. Pastore C., Nedellec R., Ramos A., Pontow S., Ratner L., Mosier D.E. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. Journal of Virology 2006, 80:750-758.
78. Pfaff J.M., Wilen C.B., Harrison J.E., Demarest J.F., Lee B., Doms R.W., Tilton J.C. HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells. Journal of Virology 2010, 84:6505-6514.
79. Pollakis G., Abebe A., Kliphuis A., Chalaby M.I., Bakker M., Mengistu Y., Brouwer M., Goudsmit J., Schuitemaker H., Paxton W.A. Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals. Journal of Virology 2004, 78:2841-2852.
80. Pollakis G., Kang S., Kliphuis A., Chalaby M.I., Goudsmit J., Paxton W.A. N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. Journal of Biological Chemistry 2001, 276:13433-13441.
81. Polzer S., Dittmar M.T., Schmitz H., Schreiber M. The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization. Virology 2002, 304:70-80.
82. Prabakaran P., Dimitrov A.S., Fouts T.R., Dimitrov D.S. Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors. Advances in Pharmacology 2007, 55:33-97.
83. Prosperi M.C., Fanti I., Ulivi G., Micarelli A., De Luca A., Zazzi M. Robust supervised and unsupervised statistical learning for HIV type 1 coreceptor usage analysis. AIDS Research and Human Retroviruses 2009, 25:305-314.
84. Puri A., Hug P., Jernigan K., Barchi J., Kim H.Y., Hamilton J., Wiels J., Murray G.J., Brady R.O., Blumenthal R. The neutral glycosphingolipid globotriaosylceramide promotes fusion mediated by a CD4-dependent CXCR4-utilizing HIV type 1 envelope glycoprotein. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:14435-14440.
85. Rawat S.S., Johnson B.T., Puri A. Sphingolipids: modulators of HIV-1 infection and pathogenesis. Bioscience Reports 2005, 25:329-343.
86. Raymond S., Delobel P., Mavigner M., Cazabat M., Souyris C., Sandres-Saune K., Cuzin L., Marchou B., Massip P., Izopet J. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 2008, 22:F11-F16.
87. Raymond S., Delobel P., Mavigner M., Ferradini L., Cazabat M., Souyris C., Sandres-Saune K., Pasquier C., Marchou B., Massip P., Izopet J. Prediction of HIV type 1 subtype C tropism by genotypic algorithms built from subtype B viruses. Journal of Acquired Immune Deficiency Syndromes 2010, 53:167-175.
88. Resch W., Hoffman N., Swanstrom R. Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 2001, 288:51-62.
89. Ringe R., Bhattacharya J. Association of enhanced HIV-1 neutralization by a single Y681H substitution in gp41 with increased gp120-CD4 interaction and macrophage infectivity. PLoS One 2012, 7:e37157.
90. Rodrigo A.G. Dynamics of syncytium-inducing and non-syncytium-inducing type 1 human immunodeficiency viruses during primary infection. AIDS Research and Human Retroviruses 1997, 13:1447-1451.
91. Ross H.A., Rodrigo A.G. Immune-mediated positive selection drives human immunodeficiency virus type 1 molecular variation and predicts disease duration. Journal of Virology 2002, 76:11715-11720.
92. Sayana S., Khanlou H. Maraviroc: a new CCR5 antagonistic. Expert Review of Anti-Infective Therapy 2009, 7:9-19.
93. Shakin-Eshleman S.H., Spitalnik S.L., Kasturi L. The amino acid at the X position of an Asn-X-Ser sequon is an important determinant of N-linked core-glycosylation efficiency. Journal of Biological Chemistry 1996, 271:6363-6366.
94. Shankarappa R., Margolick J.B., Gange S.J., Rodrigo A.G., Upchurch D., Farzadegan H., Gupta P., Rinaldo C.R., Learn G.H., He X., Huang X.L., Mullins J.I. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. Journal of Virology 1999, 73:10489-10502.
95. Shi W., Bohon J., Han D.P., Habte H., Qin Y., Cho M.W., Chance M.R. Structural characterization of HIV gp41 with the membrane-proximal external region. Journal of Biological Chemistry 2010, 285:24290-24298.
96. Shimizu N., Haraguchi Y., Takeuchi Y., Soda Y., Kanbe K., Hoshino H. Changes in and discrepancies between cell tropisms and coreceptor uses of human immunodeficiency virus type 1 induced by single point mutations at the V3 tip of the env protein. Virology 1999, 259:324-333.
97. Shimizu N., Tanaka A., Oue A., Mori T., Ohtsuki T., Apichartpiyakul C., Uchiumi H., Nojima Y., Hoshino H. Broad usage spectrum of G protein-coupled receptors as coreceptors by primary isolates of HIV. AIDS 2009, 23:761-769.
98. Sierra S., Kaiser R., Thielen A., Lengauer T. Genotypic coreceptor analysis. European Journal of Medical Research 2007, 12:453-462.
99. Simmons G., Reeves J.D., Hibbitts S., Stine J.T., Gray P.W., Proudfoot A.E., Clapham P.R. Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. Immunological Reviews 2000, 177:112-126.
100. Singh A., Page T., Moore P.L., Allgaier R.L., Hiramen K., Coovadia H.M., Walker B.D., Morris L., Ndung'u T. Functional and genetic analysis of coreceptor usage by dualtropic HIV-1 subtype C isolates. Virology 2009, 393:56-67.
101. Stawiski E., Huang W., Whitcomb J., Petropoulos C., Coakley E. Amino acid changes in gp41 of HIV-1 associated with co-receptor tropism. Antiviral Therapy 2009, 14(Suppl. 1):A133. (abstract).
102. Steckbeck J.D., Sun C., Sturgeon T.J., Montelaro R.C. Topology of the C-terminal tail of HIV-1 gp41: differential exposure of the Kennedy epitope on cell and viral membranes. PLoS One 2010, 5:e15261.
103. Suphaphiphat P., Essex M., Lee T.H. Mutations in the V3 stem versus the V3 crown and C4 region have different effects on the binding and fusion steps of human immunodeficiency virus type 1 gp120 interaction with the CCR5 coreceptor. Virology 2007, 360:182-190.
104. Suphaphiphat P., Thitithanyanont A., Paca-Uccaralertkun S., Essex M., Lee T.H. Effect of amino acid substitution of the V3 and bridging sheet residues in human immunodeficiency virus type 1 subtype C gp120 on CCR5 utilization. Journal of Virology 2003, 77:3832-3837.
105. Svicher V., Alteri C., D'Arrigo R., Laganà A., Trignetti M., Lo Caputo S., Callegaro A.P., Maggiolo F., Mazzotta F., Ferro A., Dimonte S., Aquaro S., di Pierri G., Bonora S., Tommasi C., Trotta M.P., Narciso P., Antinori A., Perno C.F., Ceccherini-Silberstein F. Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev. Antimicrobial Agents and Chemotherapy 2009, 53:2816-2823.
106. Svicher V., Chen M., Alteri C., Costa G., Dimonte S., Chang L., Parrotta L., Dimaio C., Carta S., Surdo M., Saccomandi P., Alcaro S., Ceccherini-Silberstein F., Artese A., Zhang J.M., Perno C.F. Key-genetic elements in HIV-1 gp120 V1, V2, and C4 domains tightly and differentially modulate gp120 interaction with the CCR5 and CXCR4 N-terminus and HIV-1 antigenic potential. Antiviral Therapy 2011, 16(Suppl. 1):A14.
107. Svicher V., Mercurio F., Artese A., Alteri C., Costa G., Stazi F., Salpini R., Dimonte S., Alcaro S., Perno C.F. Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 HIV-1 are specifically associated with dual tropism and modulate the interaction with CCR5 N-terminus. Program and Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections 2011, (paper 591). http://www.retroconference.org/2011/Abstracts/41821.htm.
108. Tamura K., Dudley J., Nei M., Kumar S. MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Molecular Biology and Evolution 2007, 24:1596-1599.
109. Tan K., Liu J., Wang J., Shen S., Lu M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:12303-12308.
110. Thielen A., Altmann A., Bogojeska J., Kaiser R., Lengauer T. Estimating evolutionary pathways to CXCR4 usage from cross-sectional data. Antiviral Therapy 2009, 14(Suppl. 1):A16. (abstract).
111. Thielen A., Lengauer T., Harrigan P.R., Swenson L., Dong W., McGovern R.A., Lewis M., Heera J., Valdez H. Mutation within GP41 are correlated with co-receptor tropism but do not substantialy improve co-receptor usage prediction. 8th European HIV Drug Resistance Workshop, From Basic Science to Clinical Decision Making 2010.
112. Thielen A., Lengauer T., Swenson L.C., Dong W.W., McGovern R.A., Lewis M., James I., Heera J., Valdez H., Harrigan P.R. Mutations in gp41 are correlated with coreceptor tropism but do not improve prediction methods substantially. Antiviral Therapy 2011, 16:319-328.
113. Thompson J.D., Gibson T.J., Plewniak F., Jeanmougin F., Higgins D.G. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Research 1997, 25:4876-4882.
114. Trkola A., Dragic T., Arthos J., Binley J.M., Olson W.C., Allaway G.P., Cheng-Mayer C., Robinson J., Maddon P.J., Moore J.P. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996, 384:184-187.
115. Vandekerckhove L.P., Wensing A.M., Kaiser R., Brun-Vezinet F., Clotet B., De Luca A., Dressler S., Garcia F., Geretti A.M., Klimkait T., Korn K., Masquelier B., Perno C.F., Schapiro J.M., Soriano V., Sonnerborg A., Vandamme A.M., Verhofstede C., Walter H., Zazzi M., Boucher C.A. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infectious Diseases 2011, 11:394-407.
116. Wang B., Jozwiak R., Ge Y.C., Saksena N.K. A unique, naturally occurring single-amino acid mutation in HIV type 1 V3 loop can discriminate between its cytopathicity and replication in vivo and in vitro. AIDS Research and Human Retroviruses 1998, 14:1019-1021.
117. Weissenhorn W., Dessen A., Harrison S.C., Skehel J.J., Wiley D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997, 387:426-430.
118. Williamson S. Adaptation in the env gene of HIV-1 and evolutionary theories of disease progression. Molecular Biology and Evolution 2003, 20:1318-1325.
119. Wu L., Gerard N.P., Wyatt R., Choe H., Parolin C., Ruffing N., Borsetti A., Cardoso A.A., Desjardin E., Newman W., Gerard C., Sodroski J. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996, 384:179-183.
120. Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280:1884-1888.
121. Xiang S.H., Finzi A., Pacheco B., Alexander K., Yuan W., Rizzuto C., Huang C.C., Kwong P.D., Sodroski J. A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer. Journal of Virology 2010, 84:3147-3161.
122. Xu J.Y., Gorny M.K., Palker T., Karwowska S., Zolla-Pazner S. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. Journal of Virology 1991, 65:4832-4838.
123. Yang W., Bielawski J.P., Yang Z. Widespread adaptive evolution in the human immunodeficiency virus type 1 genome. Journal of Molecular Evolution 2003, 57:212-221.
124. Zhang H., Hoffmann F., He J., He X., Kankasa C., Ruprecht R., West J.T., Orti G., Wood C. Evolution of subtype C HIV-1 Env in a slowly progressing Zambian infant. Retrovirology 2005, 2:67.
125. Zhang H., Hoffmann F., He J., He X., Kankasa C., West J.T., Mitchell C.D., Ruprecht R.M., Orti G., Wood C. Characterization of HIV-1 subtype C envelope glycoproteins from perinatally infected children with different courses of disease. Retrovirology 2006, 3:73.
126. Zhang H., Tully D.C., Zhang T., Moriyama H., Thompson J., Wood C. Molecular determinants of HIV-1 subtype C coreceptor transition from R5 to R5X4. Virology 2010, 407:68-79.
127. Zhang Y.J., Dragic T., Cao Y., Kostrikis L., Kwon D.S., Littman D.R., KewalRamani V.N., Moore J.P. Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. Journal of Virology 1998, 72:9337-9344.